TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-reported sedentary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological and clinical cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite and fever clearance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Itching at Duration of Action (16 Hours Post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Redness at Duration of Action (16 Hours Post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals seroconverting with Hepatitis B surface antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of other types of cancers in mutation carriers
Endpoint domain: Mortality/survival
Primary endpoint: Fraction of exhaled nitric oxide (FENO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Non-Progression at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline phenolic metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes against sexism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intolerance towards intimate partner violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in electroencephalographic slow-wave activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Decrease in LDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Subjective Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wear Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants reporting injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Local Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to AUC(INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-related Potential (ERP) P300 Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of White Spot Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: maximal leg power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil to lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-Term Sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Control Rate at 12 Weeks (DCR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of depressed patients showing a response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Socialization and Communication Subscale Standard Scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Use of an Effective Contraceptive Method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from baseline in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Daily Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total PFD clinical assessment scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Total Amount of Morphine Rescue Medication Required for Analgesia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hemodynamic Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Fluid responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who harassed clinic staff
Endpoint domain: Adverse events/effects
Primary endpoint: Placebo-adjusted change-from-baseline QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with increased intraprostatic lipid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak amplitude on SENSIMED Trggerfish (TF) pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dose Limiting Toxicities of ARV-110
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of PSA response rate per PCWG3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Measurement of overall RECIST response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conversion to Abnormal Maximum TAMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Fat as Measured by Bod Pod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Strength as Measured by Bench and Squat One Repetition Maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximum Oxygen Consumption as Measured by VO2max Treadmill Protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hernia recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurophysiological evaluation (braking index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Foot and Ankle Outcome Score (FAOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Enterotoxigenic Escherichia coli (ETEC) illness
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of heat-labile enterotoxin of Escherichia coli (LT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieved Clinical Response by Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Change in Body Core Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Day 84 in Ocular Discomfort Visual Analog Scale (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer specific death
Endpoint domain: Mortality/survival
Primary endpoint: Functional Outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of the CCBN test
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Endurance time differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Incidence of Death, Reinfarction, Unstable Angina Pectoris, Stroke, Unplanned Rehospitalization, Repeat Target Vessel Revascularization and Stent Thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of serious side effects like rhabdomyolysis and hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: decrease of HCV-RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: decrease of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline of Mucus Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Effector Lymphocyte Populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline of Bacterial Composition and Attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Procedural Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Multiple Breath Washout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional MP-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CGM (hours per week)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fetal weight corrected by gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate from effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of vascular risk (MMP-9, hsCRP, monocyte activation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Successful Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) (0-24) of Abacavir on Twice Daily Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Abacavir on Twice Daily Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) of Abacavir on Once Daily Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Abacavir on Once Daily Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Recorded Evoked Neural Signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measured Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Cocaine-positive Urines in Abstinent Subgroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Cocaine-positive Urines in Non-Abstinent Subgroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic value within 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Psychiatric symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Mean Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Mean Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentration level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Plasma ANP and BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of COVID-19 virus
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of days of opioid treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: bothersome nocturia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease free survival time
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Test Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Ketone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRSA Culture Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peak oscillating expiratory airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Conversion to TURBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of lab abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of dose reductions of ZW49
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with each diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHANGE in phosphorylation of intracellular target proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHANGE in messenger ribonucleic acid (mRNA) expression of target genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Emotional Intelligence Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma Clearance Estimates of Gadobutrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Distribution at Steady State (Vss) Estimates of Gadobutrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Drug Concentration-time Curve of Gadobutrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased tolerance to cow's milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: occurrence of allergic reaction to cow's milk
Endpoint domain: Adverse events/effects
Primary endpoint: Index of discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder proprioception sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder vibration sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of the perception of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preliminary efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure rate of patent ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed Response Rate (Partial Response or Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall satisfaction regarding control of diarrhea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Treatment Related AEs and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Difference in Mean Plasma Concentration of FD003 Over the 15-, 30-, and 60-minute Blood Draws on Days 1 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of time from enrollment until delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Quality of collected information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in percentage ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurological status of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of predicted lesion geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molar ratio of urinary calcium:oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of thyroid cancer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of PAT acquisitions with visible target lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiration rate correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Seizure Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first occurrence of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction With the Procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post Surgical Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of tenofovir in plasma and tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 p24 in HIV-negative biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent suppression of tissue infectivity measured by HIV-1 p24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: tmax (time at which the highest drug concentration occurs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DLPP of 20cm H2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CPAP Pre-crossover
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to CPAP Overall Study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exogenous insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose and C-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With Persistent Partial Response (PR) or Complete Response (CR) at 1 Year Since Nivolumab Discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects With Stable or Progressive Disease (SD/PD) That Convert to Complete or Partial Response (CR/PR) Upon the Addition of Ipilimumab to Nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients not meeting safety criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients successfully converted to a once daily dosing regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apolipoprotein B48 and Apolipoprotein B100 Production Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accumulation of Porphyrin (PpIX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unintended pregnancies
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of tears analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of tears analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of tears analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of tears analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratized tissue height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of native thiol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of total thiol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of disulfide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of disulfide to native thiol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (revised RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes